Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC) )
Also on site :
- This Common Over-the-Counter Medication May Harm Brain Health, Doctors Say—Do You Take It?
- In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook
- Explosion at fireworks factory in China kills 9, state media says